Naomi B. Haas, MD
Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858
Penn Medicine Provider

About me

  • Director, Prostate and Kidney Cancer Program
  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Northeastern Ohio University - College of Medicine
  • Residency: Abington Memorial Hospital
  • Fellowship: Fox Chase Cancer Center

What my patients think about me

Average Rating

708 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
addressed heart related questions
Anonymous
April 2026
my doctor is excellent
Anonymous
April 2026
dr. haas took her time and answered all my questions
Anonymous
April 2026
she was great at explaining what was going on

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Haas is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD. Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. , Diabetes Care, 37(7): 2014 ,1910-7

Haas NB, Quirt I, Hotte S, McWhirter E, Polintan R, Litwin S, Adams PD, McBryan T, Wang L, Martin LP, vonMehren M, Alpaugh RK, Zweibel J, Oza A. Phase II trial of Vorinostat in advanced melanoma , Invest New Drugs, 32(3): 2014,526-34

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , J Clin Oncol, 31(4): 2013,412-9

Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma , J Clin Oncol, 31(2): 2013,181-6

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA. , Int J Radiat Oncol Biol Phys, 83(5): 2012,1493-9

Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. , Med Oncol. (Northwood, London, England), 29(2): 2012,761-7

Swisher-McClure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, Bekelman JE. Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. , Int J Radiat Oncol Biol Phys., 83(1): 2012,8-15

Swisher-McClure S, Pollack CE, Christodouleas JP, Guzzo TJ, Haas NB, Vapiwala N, Bekelman JE. Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. , Int J Radiat Oncol Biol Phys., 83(1): 2012,8-15

Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE. Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. , Urology.: 2011

Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE. Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment. , Urology., 78(5): 2011,1107-13